Day 1 :
Keynote Forum
Michael Drues
Vascular Sciences, USA
Keynote: Conducting effective FDA pre-sub meetings: Tell don’t ask… lead don’t follow!
Time : 10:50-11:10
Biography:
Abstract:
with FDA; Communicating With FDA: How (And When) To Get It Right; 3 Tips to Vastly Improve Your FDA Communication Strategy; How to Make the Most of Your Pre-Submission Interactions with FDA How to Properly Use the FDA Pre-Submission Process and Why It's So Important; When and How To Interact With the FDA; FDA Pre-Submission Meetings: Strategies for Medtech Entrepreneurs; Communication With FDA: What Do We Say and How Do We Say It? ; Guerilla Regulatory Strategy
- Good Laboratory Practices | Good Pharmacovigilance Practices| Audits and inspections | Regulatory & Pharmacovigilance|FDA and related regulatory agencies
Location: Zurich
Chair
Eliana Silva de Moraes
ABPVS, Brazil
Co-Chair
Diadelis Remirez Figueredo
Devices and medical equipments (CECMED), Cuba
Session Introduction
Parminder Kaur
RegPak BioPharma Consulting, Netherlands
Title: Medical device vigilance in EU
Time : 13:50-14:10
Biography:
Abstract:
R C Jagessar
University of Guyana, Guyana
Title: Antimicrobial activity of the ethanolic and aqueous extract of Vicia faba L. (Fabaceae)
Time : 14:10-14:30
Biography:
Abstract:
Michael Drues
Vascular Sciences, USA
Title: The many connotations of risk and the consequences of getting them wrong
Time : 14:30-14:50
Biography:
Abstract:
P Brindha
Sastra University, India
Title: Traditional plant drugs as potential immunomodulators
Time : 14:50-15:10
Biography:
Abstract:
Rashid Mahmood
Surge Laboratories Private Limited., Pakistan
Title: Cleaning validation in pharmaceuticals
Time : 15:10-15:30
Biography:
Abstract:
Muhammad Naeem,
Indus Pharma (Pvt.) Ltd, Pakistan
Title: Roadmap to pharmaceutical regulatory harmonization in Pakistan
Time : 15:50-16:10
Biography:
Abstract:
Parminder Kaur
RegPak BioPharma Consulting, Netherlands
Title: Early access to unapproved medicines in EU
Time : 16:10-16:30
Biography:
Abstract:
Yavuz S SILAY
ICG (Istanbul Consulting Group), USA
Title: Strategic trends, current and future competitive landscape in biologics and biosimilars (follow-on biologics) drug development in USA and emerging markets-a brief snapshot from 2012 through 2022
Time : 16:30-16:50
Biography:
Abstract:
A presence in biologics and biosimilars has become a strategic priority for nearly all the world’s leading and emerging pharmaceutical companies. Below is an approximate snapshot of biologic drug sales for top 10 pharmaceutical companies during last five years and future five years will be discussed. Biosimilars or follow-on biologics are similar terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. The following topics during this presentation will be briefly discussed; Historical growth of the biologics market, Leading players, Changes to the competitive landscape 2017-2022 and Outlook for the biologics market, Leading players in 2016 vs 2022. Subsequently; Some examples of biosimilars and how it may affect the biologics will be briefly explained. While the FDA designates interchangeability, states control drug substitution laws. Once an interchangeability designation is acquired, a biosimilar may be substituted for the reference product by the pharmacist at the retail or specialty pharmacy without the intervention of the prescriber in states that have approved legislation or regulation establishing state standards for biosimilar substitution. As of January 2017, there are no interchangeable biologics approved in the U S. Biologics generally exhibit high molecular complexity, and may be quite sensitive to manufacturing process changes, unlike the more common small-molecule drugs. The follow-on manufacturer may not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product. Differences in impurities and/or breakdown products may have serious health implications. This has created a concern that copies of biologics might perform differently than the original branded version of the product. While summarizing above dynamics, the status and most recent developments in biologics and biosimilar (follow-on) drug development in United States of America and global trends will be explained.